BamSEC and AlphaSense Join Forces
Learn More

Spyre Therapeutics Inc. – Material Contracts

NASDAQ: SYRE    
Share price (6/2/26): $69.16    
Market cap (6/2/26): $6.006 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 5 pages First Amendment to Amended and Restated License Agreement
12/34/56
EX-10.1
from 8-K 11 pages Spyre Therapeutics, Inc. Amended and Restated 2016 Employee Stock Purchase Plan
12/34/56
EX-10.5
from 10-K 5 pages Notice of Restricted Stock Unit Award Spyre Therapeutics, Inc. 2016 Equity Incentive Plan
12/34/56
EX-10.1
from 10-Q 28 pages Aeglea Biotherapeutics, Inc. 2018 Equity Inducement Plan
12/34/56
EX-10.25
from 10-K 46 pages Amended and Restated License Agreement
12/34/56
EX-10.5
from 10-Q 14 pages 2.base Salary. Upon and Following the Effective Date, as Cash Compensation for Your Services, the Company Will Pay You an Initial Base Salary of $496,000 Per Year, Payable in Accordance With the Company’s Standard Payroll Schedule and Subject to Applicable Deductions and Withholdings. Your Base Salary Will Be Subject to Periodic Review and Potential Adjustment in the Company’s Discretion. Your Base Salary in Effect at Any Given Time Is Referred to Herein as the “Base Salary.” 3. Bonus Compensation
12/34/56
EX-10.4
from 10-Q 2 pages Fifth Amendment to the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan
12/34/56
EX-10.3
from 8-K 16 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Amended and Restated Cell Line License Agreement
12/34/56
EX-10.2
from 8-K 33 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Amended and Restated Biologics Master Services Agreement
12/34/56
EX-10.1
from 8-K 43 pages License Agreement
12/34/56
EX-10.7
from 10-Q 5 pages Notice of Restricted Stock Unit Award Spyre Therapeutics, Inc. 2018 Equity Inducement Plan
12/34/56
EX-10.6
from 10-Q 5 pages Notice of Stock Option Grant Spyre Therapeutics, Inc. 2016 Equity Incentive Plan
12/34/56
EX-10.5
from 10-Q 31 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Second Amended and Restated Antibody Discovery and Option Agreement
12/34/56
EX-10.4
from 10-Q 46 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. License Agreement
12/34/56
EX-10.3
from 10-Q 44 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. License Agreement
12/34/56
EX-10.6
from 10-Q 4 pages Amendment No. 1 to the Novation Agreement
12/34/56
EX-10.1
from 8-K 7 pages April 23, 2024 Spyre Therapeutics, Inc. 221 Crescent St., Building 23, Unit 105 Waltham, Ma 02453 Attention: Scott Burrows Re: 3(a)(9) Exchange Agreement Ladies and Gentlemen
12/34/56
EX-10.2
from 8-K 16 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 68 pages Securities Purchase Agreement
12/34/56
EX-10.20
from S-1/A 9 pages Consulting Agreement
12/34/56